Drug Profile
Research programme: age-related disease therapeutics - Tartis
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Tartis
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Unspecified
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 12 Sep 2023 Discontinued - Preclinical for Unspecified in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA